Short Interest in Immunic, Inc. (NASDAQ:IMUX) Increases By 14.5%
by Amy Steele · The Cerbat GemImmunic, Inc. (NASDAQ:IMUX – Get Free Report) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 7,579,660 shares, a growth of 14.5% from the February 12th total of 6,620,441 shares. Based on an average trading volume of 2,846,310 shares, the short-interest ratio is presently 2.7 days. Approximately 6.8% of the shares of the company are short sold. Approximately 6.8% of the shares of the company are short sold. Based on an average trading volume of 2,846,310 shares, the short-interest ratio is presently 2.7 days.
Institutional Investors Weigh In On Immunic
Several institutional investors and hedge funds have recently made changes to their positions in IMUX. Focus Partners Wealth raised its position in shares of Immunic by 1.5% during the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after acquiring an additional 39,063 shares during the last quarter. Laurion Capital Management LP boosted its holdings in Immunic by 106.3% in the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after acquiring an additional 2,000,000 shares during the last quarter. Millennium Management LLC boosted its holdings in Immunic by 544.6% in the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after acquiring an additional 2,888,829 shares during the last quarter. Marshall Wace LLP increased its position in Immunic by 91.2% in the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock worth $541,000 after purchasing an additional 486,468 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Immunic in the third quarter worth about $239,000. Institutional investors and hedge funds own 51.82% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages have issued reports on IMUX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. HC Wainwright decreased their price objective on shares of Immunic from $8.00 to $5.00 and set a “buy” rating for the company in a report on Monday, March 2nd. Brookline Capital Acquisition upgraded shares of Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Finally, D. Boral Capital cut their target price on shares of Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $6.00.
Get Our Latest Research Report on Immunic
Immunic Trading Up 3.4%
IMUX stock traded up $0.04 during midday trading on Tuesday, hitting $1.20. The stock had a trading volume of 2,699,646 shares, compared to its average volume of 3,835,208. Immunic has a 52 week low of $0.51 and a 52 week high of $1.51. The firm has a market capitalization of $156.55 million, a price-to-earnings ratio of -1.71 and a beta of 1.45. The stock has a 50-day simple moving average of $0.84 and a 200 day simple moving average of $0.78.
Immunic (NASDAQ:IMUX – Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, equities analysts forecast that Immunic will post -0.94 EPS for the current year.
About Immunic
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.